Therapeutic targeting of tumor-associated macrophages with anti-CD163 Nanobody-drug conjugates as novel cancer therapy

Maksymova, Liudmyla (Mandate)
Van Ginderachter, Jo (Administrative Promotor)

Description

FWO Aspirant Mandaat + benchfee
Promotor: Jo Vanginderachter

Acronym	FWOSB160
Status	Active
Effective start/end date	1/11/23 → 31/10/27

Flemish discipline codes in use since 2023

Applied immunology

Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines
Maksymova, L., Van Ginderachter, J., Nuhn, L. & Pilger, Y., 4 Mar 2025, In: Molecular Cancer. p. 65 33 p., 65.
Research output: Contribution to journal › Scientific review › peer-review

Open Access
File
19 Citations (Scopus)

SRP83: SRP-Onderzoekszwaartepunt: ITAREG: Molecular Imaging and TArgeting of immunoREGulatory cells in Inflammatory diseases and cancer
Van Ginderachter, J. (Administrative Promotor), Lahoutte, T. (CoI (Co-Promotor)), Lahoutte, T. (Administrative Promotor), Van Ginderachter, J. (Co-Promotor), Devoogdt, N. (Co-Promotor), Raes, G. (Collaborator), Stijlemans, B. (Collaborator), Vincke, C. (Collaborator) & De Groof, T. (Collaborator)
1/11/22 → 31/10/27
Project: Fundamental